Patents by Inventor Mike Rothe

Mike Rothe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human anti-IFN-? antibodies
    Patent number: 11945861
    Abstract: Provided are novel IFB-a binding molecules of human origin, particularly human-derived anti-IFN-? antibodies as well as IFN-? binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits, and methods for use in diagnosis and therapy are described.
    Type: Grant
    Filed: January 21, 2021
    Date of Patent: April 2, 2024
    Assignee: IMMUNOQURE AG
    Inventors: Syeda F. Y. Haque, Adrian Hayday, Kai Kisand, Kai Krohn, Annalisa Macagno, Steffen Meyer, Paert Peterson, Mike Rothe, Philip Vlaicu, Martin Woodward
  • ANTIBODIES DIRECTED TO HER-3 AND USES THEREOF
    Publication number: 20230059353
    Abstract: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.
    Type: Application
    Filed: March 4, 2022
    Publication date: February 23, 2023
    Applicants: DAIICHI SANKYO EUROPE GMBH, AMGEN INC.
    Inventors: MIKE ROTHE, MARTIN TREDER, ERIC BORGES, LARRY GREEN, SUSANNE HARTMANN
  • Antibodies directed to HER-3 and uses thereof
    Patent number: 11267900
    Abstract: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: March 8, 2022
    Assignees: Daiichi Sankyo Europe GmbH, Amgen Inc.
    Inventors: Mike Rothe, Martin Treder, Eric Borges, Larry L. Green, Susanne Hartmann
  • HUMAN ANTI-IFN-ALPHA ANTIBODIES
    Publication number: 20210221883
    Abstract: Provided are novel IFB-a binding molecules of human origin, particularly human-derived anti-IFN-? antibodies as well as IFN-? binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits, and methods for use in diagnosis and therapy are described.
    Type: Application
    Filed: January 21, 2021
    Publication date: July 22, 2021
    Inventors: Syeda F. Y. HAQUE, Adrian HAYDAY, Kai KISAND, Kai KROHN, Annalisa MACAGNO, Steffen MEYER, Paert PETERSON, Mike ROTHE, Philip VLAICU, Martin WOODWARD
  • CDNA encoding a monoclonal anti-IL-32 antibody and methods for the production of the antibody
    Patent number: 10975144
    Abstract: Provided are novel IL-32 binding molecules of human origin, particularly human anti-IL-32 antibodies as well as IL-32 binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy are described.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: April 13, 2021
    Assignee: ImmunoQure AG
    Inventors: Adrian Hayday, Kai Kisand, Kai Krohn, Annalisa Macagno, Shimobi Onuoha, Paert Peterson, Mike Rothe, Martin Woodward, Syeda F. Y. Haque
  • Human anti-IFN-? antibodies
    Patent number: 10941198
    Abstract: Provided are novel IFB-a binding molecules of human origin, particularly human-derived anti-IFN-? antibodies as well as IFN-? binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits, and methods for use in diagnosis and therapy are described.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: March 9, 2021
    Inventors: Syeda F. Y. Haque, Adrian Hayday, Kai Kisand, Kai Krohn, Annalisa Macagno, Steffen Meyer, Paert Peterson, Mike Rothe, Philip Vlaicu, Martin Woodward
  • ANTIBODIES DIRECTED TO HER-3 AND USES THEREOF
    Publication number: 20190263930
    Abstract: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.
    Type: Application
    Filed: October 9, 2018
    Publication date: August 29, 2019
    Applicants: DAIICHI SANKYO EUROPE GMBH, AMGEN INC.
    Inventors: MIKE ROTHE, MARTIN TREDER, ERIC BORGES, LARRY L. GREEN
  • Activated HER3 as a marker for predicting therapeutic efficacy
    Patent number: 10365283
    Abstract: The present invention provides methods for the determination of the activation level of Receptor Tyrosine kinases, e.g. phosporylated HER3, for the selection of patients for disease treatment. Methods are also provided for the evaluation of the biological and pharmacodynamic effects of an active substance and/or its efficacy in disease treatment, utilizing a tissue sample from a test subject, for example tumor material or normal tissue such as skin or hair follicle. Further, methods for the treatment of HER receptor-associated diseases are disclosed.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: July 30, 2019
    Assignee: Daiichi Sankyo Europe GmbH
    Inventors: Mike Rothe, Martin Treder
  • HUMAN ANTI-IL-32 ANTIBODIES
    Publication number: 20190112367
    Abstract: Provided are novel IL-32 binding molecules of human origin, particularly human anti-IL-32 antibodies as well as IL-32 binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy are described.
    Type: Application
    Filed: August 21, 2018
    Publication date: April 18, 2019
    Inventors: Adrian Hayday, Kai Kisand, Kai Krohn, Annalisa Macagno, Shimobi Onuoha, Paert Peterson, Mike Rothe, Martin Woodward, Syeda F. Y. Haque
  • HUMAN ANTI-IFN-ALPHA ANTIBODIES
    Publication number: 20190071499
    Abstract: Provided are novel IFB-a binding molecules of human origin, particularly human-derived anti-IFN-? antibodies as well as IFN-? binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits, and methods for use in diagnosis and therapy are described.
    Type: Application
    Filed: September 17, 2018
    Publication date: March 7, 2019
    Inventors: Syeda F. Y. HAQUE, Adrian HAYDAY, Kai KISAND, Kai KROHN, Annalisa MACAGNO, Steffen MEYER, Paert PETERSON, Mike ROTHE, Philip VLAICU, Martin WOODWARD
  • Human anti-IFN-? antibodies
    Patent number: 10112995
    Abstract: Provided are novel IFB-a binding molecules of human origin, particularly human-derived anti-IFN-? antibodies as well as IFN-? binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits, and methods for use in diagnosis and therapy are described.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: October 30, 2018
    Assignee: ImmunoQure AG
    Inventors: Syeda F. Y. Haque, Adrian Hayday, Kai Kisand, Kai Krohn, Annalisa Macagno, Steffen Meyer, Paert Peterson, Mike Rothe, Philip Vlaicu, Martin Woodward
  • Antibodies directed to HER-3 and uses thereof
    Patent number: 10100124
    Abstract: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: October 16, 2018
    Assignees: Daiichi Sankyo Europe GmbH, AMGEN, INC.
    Inventors: Mike Rothe, Martin Treder, Eric Borges, Susanne Hartmann, Larry L. Green
  • Human anti-IL-32 antibodies and methods of making and using the same
    Patent number: 10081676
    Abstract: Provided are novel IL-32 binding molecules of human origin, particularly human anti-IL-32 antibodies as well as IL-32 binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy are described.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: September 25, 2018
    Assignee: ImmunoQure AG
    Inventors: Adrian Hayday, Kai Kisand, Kai Krohn, Annalisa Macagno, Shimobi Onuoha, Paert Peterson, Mike Rothe, Martin Woodward, Syeda F. Y. Haque
  • Material and methods for treating or preventing HER-3 associated diseases
    Patent number: 9988462
    Abstract: Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example.
    Type: Grant
    Filed: January 18, 2016
    Date of Patent: June 5, 2018
    Inventors: Thore Hettmann, Daniel J. Freeman, Robert Radinsky, Mike Rothe
  • HUMAN ANTI-IFN-ALPHA ANTIBODIES
    Publication number: 20170051055
    Abstract: Provided are novel IFN-? binding molecules of human origin, particularly human-derived anti-IFN-? antibodies as well as IFN-? binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy are described.
    Type: Application
    Filed: July 3, 2014
    Publication date: February 23, 2017
    Inventors: Syeda F.Y. HAQUE, Adrian HAYDAY, Kai KISAND, Kai KROHN, Annalisa MACAGNO, Steffen MEYER, Paert PETERSON, Mike ROTHE, Philip VLAICU, Martin WOODWARD
  • HUMAN ANTI-IL-32 ANTIBODIES
    Publication number: 20160368981
    Abstract: Provided are novel IL-32 binding molecules of human origin, particularly human anti-IL-32 antibodies as well as IL-32 binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy are described.
    Type: Application
    Filed: July 3, 2014
    Publication date: December 22, 2016
    Inventors: Andrian HAYDAY, Kai KISAND, Kai KROHN, Annalisa MACAGNO, Shimobi ONUOHA, Paert PETERSON, Mike ROTHE, Martin WOODWARD, Syeda F.Y. HAQUE
  • MATERIAL AND METHODS FOR TREATING OR PREVENTING HER-3 ASSOCIATED DISEASES
    Publication number: 20160222126
    Abstract: Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example.
    Type: Application
    Filed: January 18, 2016
    Publication date: August 4, 2016
    Applicants: U3 PHARMA GMBH, AMGEN, INC.
    Inventors: Thore Hettmann, Daniel J. Freeman, Robert Radinsky, Mike Rothe
  • ANTIBODIES DIRECTED TO HER-3 AND USES THEREOF
    Publication number: 20160168264
    Abstract: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.
    Type: Application
    Filed: December 15, 2015
    Publication date: June 16, 2016
    Applicants: U3 PHARMA GMBH, AMGEN, INC.
    Inventors: MIKE ROTHE, MARTIN TREDER, ERIC BORGES, SUSANNE HARTMANN, LARRY L. GREEN
  • ACTIVATED HER3 AS A MARKER FOR PREDICTING THERAPEUTIC EFFICACY
    Publication number: 20160161491
    Abstract: The present invention provides methods for the determination of the activation level of Receptor Tyrosine kinases, e.g. phosporylated HER3, for the selection of patients for disease treatment. Methods are also provided for the evaluation of the biological and pharmacodynamic effects of an active substance and/or its efficacy in disease treatment, utilizing a tissue sample from a test subject, for example tumor material or normal tissue such as skin or hair follicle. Further, methods for the treatment of HER receptor-associated diseases are disclosed.
    Type: Application
    Filed: February 18, 2016
    Publication date: June 9, 2016
    Applicant: U3 PHARMA GMBH
    Inventors: Mike ROTHE, Martin TREDER
  • FGFR4 antibodies
    Patent number: 9284379
    Abstract: The present invention relates to FGFR4 antibodies including fragments or derivatives thereof and the polynucleotides encoding the antibodies. Expression vectors and host cells comprising the polynucleotides are provided. Further, the invention refers to pharmaceutical compositions comprising the FGFR4 antibodies and methods for the treatment, prevention or diagnosis of disorders associated with FGFR4 expression.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: March 15, 2016
    Assignee: U3 Pharma GmbH
    Inventors: Johannes Bange, Jens Niewoehner, Patricia Aus Dem Siepen, Mike Rothe